Dr. Khuri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
305 E 47th St
New York, NY 10017Phone+1 404-550-4199
Summary
- Dr. Fadlo Khuri is an oncologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Emory University Hospital, Grady Memorial Hospital, and Emory University Hospital Midtown. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice 28 years. He specializes in head & neck cancer, hematologic oncology, and thoracic cancer and is experienced in thoracic oncology.
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Boston University Medical CenterResidency, Internal Medicine, 1989 - 1992
Columbia University Vagelos College of Physicians and SurgeonsClass of 1989
Certifications & Licensure
GA State Medical License 2002 - 2019
TX State Medical License 1995 - 2015
MA State Medical License 1992 - 2014
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Atlanta Magazine: Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2008-2013
- Join now to see all
Clinical Trials
- S0000 Selenium and Vitamin E in Preventing Prostate Cancer Start of enrollment: 2001 Jul 01
- Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Start of enrollment: 2004 Dec 01
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- Corrigendum to "Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk ...Yikun Li, Ping Yue, Xingming Deng, Takeshi Ueda, Rikiro Fukunaga
Neoplasia. 2024-10-01 - Correction for Puckett et al., "Integration of Apoptosis Signal-Regulating Kinase 1-Mediated Stress Signaling with the Akt/Protein Kinase B-IκB Kinase Cascade".Mary C Puckett, Erinn H Goldman, Lisa M Cockrell, Bei Huang, Andrea L Kasinski
Molecular and Cellular Biology. 2022-10-20 - 4 citationsA Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.Julie E Bauman, Zhengjia Chen, Chao Zhang, James P Ohr, Robert L Ferris
Cancers. 2022-05-26
Journal Articles
- Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative AnalysisRathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
- Article MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationGuojing Zhang, Fadlo R Khuri, Taofeek K Owonikoko, Dan Li, Conor E Steuer, Nabil F Saba, Dong M Shin, Sagar Lonial, ScienceDirect
Press Mentions
You Must Be Present to WinDecember 1st, 2021- Executive Profile: Dr. Suresh Ramalingam Pursues Cancer Research and Patient CareSeptember 27th, 2021
- Dr. Zaher Dawy Appointed as Provost and Dr. Lina Choueiri as Deputy Provost at AUBJuly 14th, 2021
- Join now to see all
Grant Support
- Discovery And Developmental Therapeutics (DDT)National Cancer Institute2009–2011
- Career Development ProgramNational Cancer Institute2007–2011
- Targeting Cell Signaling In Lung Cancer To Enhance Therapeutic EfficacyNational Cancer Institute2006–2010
- Modulation Of The Mtor Pathway For Lung Cancer TreatmentNational Cancer Institute2006–2010
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
